SolnMat™
Biomaterial Composite Design Platform
SolnMat™
Biomaterial Composite Design Platform
Predictive Design for Biomaterial Innovation.
Accelerating Translational Research from Lab to Clinic.
Integrating multi-physics simulation with AI performance prediction, SolnMat™ enables high-precision modeling of microsphere suspension, material degradation, and drug release behavior—transforming development from trial-and-error to intelligent design, reducing experimental workload by over 50%, and shortening IND submission timelines by more than one year.
-
Precision Simulation
Multi-physics coupling computation (CFD + FEA) simulates microsphere suspension and scaffold mechanical decay. -
Accelerated Translation
Shortens IND submission timelines by over one year, with experimental workload reduced by more than 50%. -
Interface Optimization
Predicts material-cell interactions to guide surface functionalization design. -
Clinical Validation
Supported PLLA microspheres through 240+ patient clinical enrollment (Class III medical device). -
Performance Prediction
Predicts degradation kinetics, mechanical strength, and drug release profiles. -
Technical Breakthrough
Dual decellularization process; ECM materials scheduled to initiate clinical-exemption registration in 2027.
SolnMat™
Biomaterial Composite Design Platform
SolnMat™
Biomaterial Composite Design Platform
Predictive Design for Biomaterial Innovation.
Accelerating Translational Research from Lab to Clinic.
Integrating multi-physics simulation with AI performance prediction, SolnMat™ enables high-precision modeling of microsphere suspension, material degradation, and drug release behavior—transforming development from trial-and-error to intelligent design, reducing experimental workload by over 50%, and shortening IND submission timelines by more than one year.
-
Precision Simulation
Multi-physics coupling computation (CFD + FEA) simulates microsphere suspension and scaffold mechanical decay. -
Accelerated Translation
Shortens IND submission timelines by over one year, with experimental workload reduced by more than 50%. -
Interface Optimization
Predicts material-cell interactions to guide surface functionalization design. -
Clinical Validation
Supported PLLA microspheres through 240+ patient clinical enrollment (Class III medical device). -
Performance Prediction
Predicts degradation kinetics, mechanical strength, and drug release profiles. -
Technical Breakthrough
Dual decellularization process; ECM materials scheduled to initiate clinical-exemption registration in 2027.
Intelligent Regenerative Biomaterials Pipeline
Project |
Indication |
Design Input |
Design Output |
Design Verification |
Design Validation |
Regulatory Submission |
Commercial Rights |
|---|---|---|---|---|---|---|---|
| Medical Devices > | |||||||
| APR-301Key Component | Recombinant Collagen, Sodium Hyaluronate | Non-Chronic Wounds and Surrounding Skin |
|
 |
||||
| APR-202Key Component | dECM | Endometrial Injury |
|
|
||||
| APR-102Key Component | dECM | Focal Cartilage Defects |
|
|
||||
| APR-101Key Component | PLLA Microspheres | Moderate-to-Severe Nasolabial Folds |
|
|
||||
| Drug-Device Combination Products > | |||||||
| APR-401Key Component | dECM, Stem Cells | Arthritis, Knee Joint Injury |
|
|
||||
SUNRAY R&D Pipeline
Medical Devices
-
APR-101
PLLA Poly-L-Lactic Acid Microspheres (Class III Medical Device)
Injectable PLLA microspheres designed to correct moderate-to-severe nasolabial folds by stimulating autologous collagen regeneration, achieving natural and progressive facial rejuvenation.
Mechanism of Action
AI-assisted designed PLLA microspheres, injected into the deep dermis, continuously stimulate fibroblasts to produce collagen, with filler degradation and collagen regeneration kinetics matched to achieve natural tissue volume restoration.
Unmet Need
Traditional fillers provide only temporary physical volumization with short duration; non-uniform particle size and high inflammatory response preclude sustained tissue regeneration.
Current Status
Class III medical device clinical trial initiated in March 2026 across 6 sites, with Peking Union Medical College Hospital as the lead center; 248-patient enrollment completed in Q2 2026; full clinical follow-up expected to complete in Q4 2027.
-
APR-201
dECM Cartilage Repair Scaffold (Class III Medical Device)
A decellularized extracellular matrix (dECM) cartilage repair scaffold designed for use in conjunction with microfracture surgery, enabling regenerative repair of articular cartilage defects by mimicking the native cartilage microenvironment.
Mechanism of Action
The scaffold's three-dimensional microstructure provides a niche for autologous mesenchymal stem cell adhesion, proliferation, and differentiation; retained growth factors including TGF-β and BMP-2 induce chondrogenic differentiation of stem cells.
Unmet Need
Fibrocartilage formed by conventional microfracture surgery exhibits poor mechanical properties and is prone to degeneration; scaffold materials capable of inducing hyaline cartilage regeneration are lacking.
Current Status
Pilot- and mid-scale production completed; scale-up production and animal studies underway; clinical trial initiation expected in early 2027.
-
APR-301
Recombinant Collagen Dressing (Class II Medical Device)
A sterile medical dressing composed of recombinant collagen lyophilized sponge and sodium hyaluronate solution for the care of non-chronic wounds and surrounding skin.
Mechanism of Action
AI machine learning models intelligently match the recombinant collagen and sodium hyaluronate ratio to achieve synergistic efficacy, dynamically generating personalized dressing formulations based on different skin types and wound conditions.
Unmet Need
Conventional dressings rely on fixed formulations that cannot adapt to varying wound conditions, resulting in suboptimal repair efficiency.
Current Status
Medical device registration quality management system review and production license inspection have been completed;the registration supplement is currently under review; Class II medical device approval expected in June 2026.
-
APR-401
ECM Endometrial Repair Material
A decellularized extracellular matrix (dECM) endometrial repair material implanted via non-invasive instillation to repair endometrial injury and restore fertility.
Mechanism of Action
AI degradation kinetic models predict the scaffold's degradation rate within the uterine cavity, matching the natural endometrial repair cycle; non-invasive instillation procedure ensures good retention while providing cellular scaffolding and bioactive signaling.
Unmet Need
Endometrial injury is the leading cause of female infertility (accounting for over 40%), with suboptimal therapeutic outcomes; patients' low willingness to receive preventive treatment contributes to high infertility rates.
Current Status
Pilot-, mid-scale, and scale-up production completed; pre-registration preparation underway; medical device registration submission expected in June 2026, with approval anticipated in Q4 2026.
Regenerative Medicine Combination Products
-
APR-202
dECM Combined with Stem Cells for Knee Joint Repair (Drug-Device Combination Product)
dECM scaffold combined with autologous stem cells, precisely mimicking the physiological microenvironment of the knee joint to provide an ideal "niche" for stem cells, achieving synergistic regenerative repair of degenerative joint disease.
Mechanism of Action
AI-powered cell screening platform selects stem cell subpopulations with high differentiation potential and low tumorigenic risk; the ECM scaffold's native collagen, glycosaminoglycans, laminin, and growth factors promote stem cell homing, adhesion, and differentiation.
Unmet Need
Stem cell injection alone suffers from low retention rates and uncertain differentiation trajectories; conventional scaffolds lack bioactive signals. The synergistic approach targets degenerative joint disease at its root.
Current Status
Early-stage research phase; completion expected in Q2 2026.